OBSEVA SA (OBSV)       0.2126  +0.01 (+2.56%)

0.2126  +0.01 (+2.56%)

CH0346177709 - Common Stock - After market: 0.2115 0 (-0.52%)


Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OBSV. OBSV was compared to 639 industry peers in the Biotechnology industry. Both the profitability and financial health of OBSV have multiple concerns. OBSV is quite expensive at the moment. It does show a decent growth rate.

Note: OBSV has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

OBSV has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of OBSV.

VS Industry

Valuation

Valuation Rating

0

OBSV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year OBSV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

6

The Earnings Per Share is expected to grow by 26.26% on average over the next 5 years. This is a very strong growth
The Revenue has been growing by 298.56% on average over the past 5 years. This is a very strong growth!
The Revenue is expected to grow by 11.07% on average over the next 5 years. This is quite good.

The Earnings Per Share has been growing slightly by 6.94% over the past year.
The Revenue for OBSV has decreased by -57.43% in the past year. This is quite bad
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 6.94% 12.85% 32.71% 26.26% N/A
Revenue298.56% 901.88% -57.43% -33.03% -41.42% 14.26% 11.07%

Health

Health Rating

0

A Current Ratio of 0.61 indicates that OBSV may have some problems paying its short term obligations.
Compared to an average industry Current Ratio of 6.21, OBSV is worse placed to pay its short term obligations than its industry peers. 97% of its industry peers have a better Current Ratio.
OBSV has a Quick Ratio of 0.61. This is a bad value and indicates that OBSV is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Quick Ratio of 6.11, OBSV is worse placed to pay its short term obligations than its industry peers. 97% of its industry peers have a better Quick Ratio.

Based on the Altman-Z score of -45.29, we must say that OBSV is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.13, OBSV is in worse financial state than most of its industry peers. 98% of its industry peers have a better Altman-Z score.
OBSV has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of OBSV.
VS Industry

Quick Ratio (0.61) VS Industry: 3% outperformed.

0.04
84.53

Current Ratio (0.61) VS Industry: 3% outperformed.

0.08
85.09

Altman-Z (-45.29) VS Industry: 2% outperformed.

-94.22
622.88

Dividend

Dividend Rating

0

No dividends for OBSV!.

OBSEVA SA0.2126

NASDAQ:OBSV (1/27/2023, 7:25:41 PM)+0.01 (+2.56%)

After market: 0.2115 0 (-0.52%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 12-01 2022-12-01/amc Earnings (Next) 03-06 2023-03-06
Inst Owners 16.17% Inst Owner Change 0%
Ins Owners 2.48% Ins Owner Change 0%
Market Cap 17.96M Analysts 77.78
Price Target 6.63 (3018.53%)

Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) -11.4%
Min EPS beat(2) -121.65% Max EPS beat(2) 98.85%
EPS beat(4) 2 Avg EPS beat(4) -2.12%
Min EPS beat(4) -121.65% Max EPS beat(4) 98.85%
Revenue beat(2) 2 Avg Revenue beat(2) 51188.3%
Min Revenue beat(2) 45.28% Max Revenue beat(2) 102331%
Revenue beat(4) 3 Avg Revenue beat(4) 25589.6%
Min Revenue beat(4) -40.77% Max Revenue beat(4) 102331%
PT rev (1m) 39.28% EPS NQ rev (1m) 0%
EPS NY rev (1m) 0% Revenue NQ rev (1m) N/A
Revenue NY rev (1m) 0%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM) -0.79 EY N/A
EPS(NY) -0.19 Fwd EY N/A
FCF(TTM) -0.52 FCFY N/A
OCF(TTM) -0.52 OCFY N/A
SpS 0.1 BVpS -0.04
TBVpS -0.09 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 3 Asset Turnover 0.51

Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.29%
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.61
Altman-Z -45.29
F-Score 3 WACC 10.03%
ROIC/WACC N/A Cap/Depr(3y) 228.57%
Cap/Depr(5y) 1654.55% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 6.94% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -110%
EPS Next Y 12.85% EPS Next 2Y 32.71%
EPS Next 3Y 26.26% EPS Next 5Y N/A
Revenue growth 1Y -57.43% Revenue growth 3Y 901.88%
Revenue growth 5Y 298.56% Revenue growth Q2Q -81.53%
Revenue Next Year -33.03% Revenue Next 2Y -41.42%
Revenue Next 3Y 14.26% Revenue Next 5Y 11.07%
EBIT growth 1Y 23.88% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y 42.99% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y 39.03%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA